217 related articles for article (PubMed ID: 24007864)
1. Non-viral causes of liver cancer: does obesity led inflammation play a role?
Alzahrani B; Iseli TJ; Hebbard LW
Cancer Lett; 2014 Apr; 345(2):223-9. PubMed ID: 24007864
[TBL] [Abstract][Full Text] [Related]
2. NAFLD leads to liver cancer: do we have sufficient evidence?
Duan XY; Zhang L; Fan JG; Qiao L
Cancer Lett; 2014 Apr; 345(2):230-4. PubMed ID: 23941829
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.
Torres DM; Harrison SA
Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886
[TBL] [Abstract][Full Text] [Related]
5. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
6. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.
Tajima K; Nakamura A; Shirakawa J; Togashi Y; Orime K; Sato K; Inoue H; Kaji M; Sakamoto E; Ito Y; Aoki K; Nagashima Y; Atsumi T; Terauchi Y
Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E987-98. PubMed ID: 23964070
[TBL] [Abstract][Full Text] [Related]
7. NASH and HCC.
Page JM; Harrison SA
Clin Liver Dis; 2009 Nov; 13(4):631-47. PubMed ID: 19818310
[TBL] [Abstract][Full Text] [Related]
8. Role of chronic inflammation in cancers of the gastrointestinal system and the liver: where we are now.
Qiao L; Li X
Cancer Lett; 2014 Apr; 345(2):150-2. PubMed ID: 24246847
[No Abstract] [Full Text] [Related]
9. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
10. Obesity, insulin resistance, NASH and hepatocellular carcinoma.
Yu J; Shen J; Sun TT; Zhang X; Wong N
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):483-91. PubMed ID: 23876851
[TBL] [Abstract][Full Text] [Related]
11. Obesity-associated mechanisms of hepatocarcinogenesis.
Karagozian R; Derdák Z; Baffy G
Metabolism; 2014 May; 63(5):607-17. PubMed ID: 24629562
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.
Baffy G; Brunt EM; Caldwell SH
J Hepatol; 2012 Jun; 56(6):1384-91. PubMed ID: 22326465
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.
Dyson J; Jaques B; Chattopadyhay D; Lochan R; Graham J; Das D; Aslam T; Patanwala I; Gaggar S; Cole M; Sumpter K; Stewart S; Rose J; Hudson M; Manas D; Reeves HL
J Hepatol; 2014 Jan; 60(1):110-7. PubMed ID: 23978719
[TBL] [Abstract][Full Text] [Related]
14. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer.
Friedbichler K; Themanns M; Mueller KM; Schlederer M; Kornfeld JW; Terracciano LM; Kozlov AV; Haindl S; Kenner L; Kolbe T; Mueller M; Snibson KJ; Heim MH; Moriggl R
Hepatology; 2012 Mar; 55(3):941-52. PubMed ID: 22031092
[TBL] [Abstract][Full Text] [Related]
15. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease.
Videla LA; Rodrigo R; Araya J; Poniachik J
Trends Mol Med; 2006 Dec; 12(12):555-8. PubMed ID: 17049925
[TBL] [Abstract][Full Text] [Related]
16. Positive effect of curcumin on inflammation and mitochondrial dysfunction in obese mice with liver steatosis.
Kuo JJ; Chang HH; Tsai TH; Lee TY
Int J Mol Med; 2012 Sep; 30(3):673-9. PubMed ID: 22751848
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
Schuppan D; Schattenberg JM
J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.
Cuadrado A; Orive A; García-Suárez C; Domínguez A; Fernández-Escalante JC; Crespo J; Pons-Romero F
Obes Surg; 2005 Mar; 15(3):442-6. PubMed ID: 15826485
[TBL] [Abstract][Full Text] [Related]
19. [Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis].
Jansen PL
Ned Tijdschr Geneeskd; 2005 Feb; 149(6):289-94. PubMed ID: 15730035
[TBL] [Abstract][Full Text] [Related]
20. HCC and NASH: how strong is the clinical demonstration?
Rosmorduc O; Fartoux L
Clin Res Hepatol Gastroenterol; 2012 Jun; 36(3):202-8. PubMed ID: 22326764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
